Cidara Therapeutics, Inc. (NASDAQ:CDTX) received a $15.00 price objective from Cantor Fitzgerald in a research note issued on Thursday. The firm currently has a “buy” rating on the biotechnology company’s stock. Cantor Fitzgerald’s price target suggests a potential upside of 141.94% from the stock’s current price.

CDTX has been the subject of a number of other research reports. ValuEngine lowered Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. BTIG Research restated a “buy” rating and set a $20.00 price objective (up from $15.00) on shares of Cidara Therapeutics in a research report on Saturday, April 29th. Wedbush restated an “outperform” rating and set a $13.00 price objective on shares of Cidara Therapeutics in a research report on Tuesday, May 16th. HC Wainwright restated a “buy” rating and set a $14.00 price objective (down from $18.00) on shares of Cidara Therapeutics in a research report on Monday, April 17th. Finally, Zacks Investment Research lowered Cidara Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Cidara Therapeutics currently has an average rating of “Buy” and a consensus target price of $13.14.

Cidara Therapeutics (NASDAQ CDTX) traded down 4.62% on Thursday, reaching $6.20. 202,360 shares of the company’s stock were exchanged. The stock’s market capitalization is $104.20 million. The firm’s 50 day moving average is $7.33 and its 200 day moving average is $7.55. Cidara Therapeutics has a 1-year low of $5.65 and a 1-year high of $12.95.

Cidara Therapeutics (NASDAQ:CDTX) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.99) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.91) by $0.08. Analysts expect that Cidara Therapeutics will post ($3.52) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was illegally copied and reposted in violation of United States & international copyright and trademark law. The legal version of this report can be read at https://www.dailypolitical.com/2017/08/10/cidara-therapeutics-inc-cdtx-given-a-15-00-price-target-at-cantor-fitzgerald.html.

In other Cidara Therapeutics news, CEO Jeffrey Stein acquired 15,000 shares of the firm’s stock in a transaction on Monday, June 5th. The stock was purchased at an average cost of $5.95 per share, for a total transaction of $89,250.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Taylor Sandison acquired 20,000 shares of the firm’s stock in a transaction on Wednesday, June 7th. The shares were acquired at an average price of $5.90 per share, with a total value of $118,000.00. The disclosure for this purchase can be found here. Company insiders own 18.90% of the company’s stock.

Several large investors have recently made changes to their positions in the stock. Trexquant Investment LP purchased a new stake in shares of Cidara Therapeutics during the second quarter valued at about $110,000. Teachers Advisors LLC raised its stake in shares of Cidara Therapeutics by 17.5% in the fourth quarter. Teachers Advisors LLC now owns 16,524 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 2,458 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Cidara Therapeutics during the fourth quarter valued at about $173,000. JPMorgan Chase & Co. raised its stake in shares of Cidara Therapeutics by 455.6% in the first quarter. JPMorgan Chase & Co. now owns 25,639 shares of the biotechnology company’s stock valued at $200,000 after buying an additional 21,024 shares in the last quarter. Finally, Spark Investment Management LLC purchased a new stake in shares of Cidara Therapeutics during the first quarter valued at about $227,000. Institutional investors and hedge funds own 68.46% of the company’s stock.

About Cidara Therapeutics

Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.